Evidence map›Paper›PMID 34338149›Full record

ArticleBioengineered2021

Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells.

Ling Li, Kelei Qian, Yuli Sun, Yong Zhao, Yun Zhou, Ying Xue, Xinyu Hong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus.The Journal of clinical endocrinology and metabolism · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ling LiDepartment of Endocrinology, Tongji Hospital of Tongji University, Tongji University School of Medicine, Shanghai, China.
Kelei QianDepartment of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Yuli SunDepartment of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Yong ZhaoDepartment of Endocrinology, Tongji Hospital of Tongji University, Tongji University School of Medicine, Shanghai, China.
Yun ZhouDepartment of Endocrinology, Tongji Hospital of Tongji University, Tongji University School of Medicine, Shanghai, China.
Ying XueDepartment of Endocrinology, Tongji Hospital of Tongji University, Tongji University School of Medicine, Shanghai, China.
Xinyu HongDepartment of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-1298-1585
Tongji University · CNTaiwan Centers for Disease Control · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic nephropathy (DN) is a complication of diabetes that induces the development of end-stage renal disease (ESRD). The pathogenesis of DN is reported to be closely related to the activation of the NOD-like receptor 3 (NLRP3) inflammasome in renal glomerular endothelial cells. Omarigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the management of type II diabetes, it has been recently reported to possess a significant anti-inflammatory property. This study aims to explore the potential therapeutic effects of Omarigliptin on DN. We established an

Indexed as

Adenosine MonophosphateAMP-Activated Protein KinasesCells, CulturedCell SurvivalDiabetic NephropathiesGlucoseHeterocyclic Compounds, 2-RingHumansInflammasomesKidney GlomerulusNLR Family, Pyrin Domain-Containing 3 ProteinPyransSignal Transduction2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amineAdenosine MonophosphateAMP-Activated Protein KinasesGlucoseHeterocyclic Compounds, 2-RingInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanPyransAMPKdiabetic nephropathyNLRP3 inflammasomeOmarigliptin

Identifiers

PMID34338149
PMCPMC8806494
OpenAlexW3192828323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.